GALT Stock Price, Galectin Therapeutics Quote, Chart

Market Summary

USD3.60+0.15

Delayed

4.35%

GALT Stock Price

View Fullscreen

GALT RSI Chart

GALT Valuation

Market Cap

222.9M

Price/Earnings (Trailing)

-5.43

Price/Free Cashflow

-6.76

GALT Price/Sales (Trailing)

GALT Profitability

Return on Equity

66.27%

Return on Assets

-145.62%

Free Cashflow Yield

-14.79%

GALT Fundamentals

GALT Earnings

Earnings (TTM)

-41.1M

Earnings Growth (Yr)

5.99%

Earnings Growth (Qtr)

4.13%

Breaking Down GALT Revenue

Last 7 days

17.7%

Last 30 days

50.6%

Last 90 days

105.7%

Trailing 12 Months

104.6%

How does GALT drawdown profile look like?

GALT Financial Health

Current Ratio

1.77

GALT Investor Care

Shares Dilution (1Y)

4.14%

Diluted EPS (TTM)

-0.74

Tracking the Latest Insider Buys and Sells of Galectin Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 24, 2024	lewis joel	bought	3,390	3.39	1,000	president and ceo
Apr 23, 2024	czirr james c	sold	-11,251	3.06	-3,677	-
Apr 22, 2024	freeman kevin d	bought	7,450	2.98	2,500	-
Apr 22, 2024	czirr james c	sold	-65,248	3.06	-21,323	-
Apr 09, 2024	freeman kevin d	acquired	-	-	2,063	-
Mar 01, 2024	lewis joel	sold	-299,065	1.96	-152,584	president and ceo
Jan 24, 2024	uihlein richard e	acquired	40,000	1.72	23,256	-
Jan 16, 2024	eldred kary	bought	892	1.7858	500	-
Dec 29, 2023	lewis joel	acquired	19,266	1.66	11,606	president and ceo
Dec 15, 2023	lewis joel	acquired	19,267	1.6	12,042	president and ceo

Which funds bought or sold GALT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-38,313	-	-%
Apr 25, 2024	Bogart Wealth, LLC	sold off	-	-	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	13.18	7,000	18,000	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	reduced	-4.3	80,000	290,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	143	598	-%
Apr 23, 2024	Summit Trail Advisors, LLC	unchanged	-	14,600	47,800	-%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-6,308	-	-%
Apr 19, 2024	RETIREMENT GUYS FORMULA LLC	added	56.89	44,929	80,619	0.04%
Apr 17, 2024	BARRETT & COMPANY, INC.	unchanged	-	2,799	9,163	-%
Apr 16, 2024	Stratos Wealth Partners, LTD.	unchanged	-	29,529	96,676	-%

Are Funds Buying or Selling GALT?

Are funds buying GALT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GALT

No. of Funds

Unveiling Galectin Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 01, 2023	10x fund, l.p.	9.6%	5,947,207	SC 13D/A

Recent SEC filings of Galectin Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	5	Insider Trading
Apr 22, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Mar 29, 2024	10-K	Annual Report
Mar 29, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Feb 16, 2024	3	Insider Trading
Feb 07, 2024	4	Insider Trading

Peers (Alternatives to Galectin Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Galectin Therapeutics Inc News

Latest updates

Galectin Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	27.2%	28.00	22.00	20.00	20.00	21.00	18.00	26.00	34.00	42.00	38.00	33.00	23.00	30.00	34.00	41.00	44.00	48.00	51.00	53.00	8.00	9.00
Current Assets	28.2%	28.00	22.00	19.00	20.00	21.00	17.00	26.00	34.00	42.00	38.00	33.00	23.00	29.00	34.00	41.00	44.00	48.00	50.00	53.00	7.00	9.00
Cash Equivalents	26.0%	26.00	20.00	18.00	18.00	19.00	16.00	24.00	32.00	40.00	37.00	32.00	21.00	27.00	33.00	41.00	43.00	47.00	50.00	52.00	7.00	8.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	21.1%	88.00	73.00	71.00	63.00	53.00	40.00	41.00	40.00	39.00	29.00	16.00	5.00	5.00	3.00	4.00	1.00	3.00	1.00	1.00	1.00	2.00
Current Liabilities	49.0%	16.00	11.00	10.00	12.00	13.00	10.00	11.00	10.00	9.00	8.00	6.00	5.00	5.00	2.00	4.00	1.00	3.00	1.00	1.00	1.00	2.00
Shareholder's Equity	-Infinity%	-61.96	-	-	-	-33.92	-	-	-	1.00	8.00	15.00	17.00	22.00	30.00	35.00	41.00	44.00	48.00	50.00	5.00	5.00
Retained Earnings	-2.9%	-354	-344	-330	-321	-309	-298	-290	-280	-270	-263	-254	-246	-240	-232	-226	-219	-216	-211	-208	-205	-196
Additional Paid-In Capital	0.2%	292	291	277	276	275	274	273	272	271	270	270	262	262	261	261	260	260	258	258	210	194
Shares Outstanding	0.0%	62.00	62.00	60.00	60.00	59.00	59.00	59.00	59.00	59.00	58.00	58.00	57.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	63.00	-	-	-	59.00	-	-	-	139	-	-	-	126	-	-	-	166	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	38.4%	-4,702	-7,637	-9,833	-10,793	-7,239	-8,347	-7,428	-8,042	-6,951	-4,998	-5,977	-6,382	-5,414	-8,212	-2,604	-4,371	-3,759	-1,475	-2,330	-3,284	-2,007
Share Based Compensation	-15.2%	497	586	516	662	681	681	647	858	654	587	581	254	567	408	394	430	414	414	443	412	1,152
Cashflow From Financing	-0.3%	10,000	10,033	10,000	10,000	10,000	-	-	-	9,999	10,000	16,815	-	-	-	44.00	219	902	-231	47,401	2,003	124

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GALT Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 32,130	$ 31,737
General and administrative	5,942	6,615
Total operating expenses	38,072	38,352
Total operating loss	(38,072)	(38,352)
Other income (expense):
Interest income	230	52
Interest expense	(2,792)	(1,033)
Change in fair value of derivatives	(432)	557
Total other expense	(2,994)	(424)
Net loss	(41,066)	(38,776)
Preferred stock dividends	(120)	(97)
Warrant modification	(3,619)	0
Net loss applicable to common stockholders	$ (44,805)	$ (38,873)
Net loss per common share - basic (in dollars per share)	$ (0.74)	$ (0.65)
Net loss per common share - diluted (in dollars per share)	$ (0.74)	$ (0.65)
Weighted average common and potential common shares outstanding - basic (in shares)	60,159	59,391
Weighted average common and potential common shares outstanding - diluted (in shares)	60,159	59,391

GALT Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 25,660	$ 18,592
Prepaid expenses and other current assets	2,050	1,960
Total current assets	27,710	20,552
Property and equipment, net	0	0
Other	490	733
Total assets	28,200	21,285
Current liabilities:
Accounts payable	6,431	3,890
Accrued expenses	9,182	9,058
Accrued dividends payable	63	64
Total current liabilities	15,676	13,012
Convertible notes payable and accrued interest, net of discounts - related party (Note 5)	30,902	29,964
Derivative liabilities (Note 6)	1,004	573
Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 10)	40,839	9,864
Other liabilities	20	66
Total liabilities	88,441	53,479
Commitments and contingencies (Note 12)
Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2023 and 2022, redemption value: $8,177,000, liquidation value: $1,786,000 at December 31,2023	1,723	1,723
Stockholders' equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2023 and 2022, 20,000,000 shares designated at December 31, 2023 and 2022, respectively	0	0
Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,235,000 and 1,260,000 issued and outstanding at December 31, 2023 and 2022, respectively, liquidation value $1,235,000 at December 31, 2023	500	510
Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2023 and 2022, 61,852,914 and 59,426,005 issued and outstanding at December 31, 2023 and 2022, respectively	61	59
Additional paid-in capital	291,847	275,081
Accumulated deficit	(354,372)	(309,567)
Total stockholders' deficit	(61,964)	(33,917)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	$ 28,200	$ 21,285

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

CEO	Mr. Joel Lewis
WEBSITE	https://galectintherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Galectin Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Galectin Therapeutics Inc? What does GALT stand for in stocks?

GALT is the stock ticker symbol of Galectin Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Galectin Therapeutics Inc (GALT)?

As of Mon Apr 29 2024, market cap of Galectin Therapeutics Inc is 222.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GALT stock?

You can check GALT's fair value in chart for subscribers.

What is the fair value of GALT stock?

You can check GALT's fair value in chart for subscribers. The fair value of Galectin Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Galectin Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GALT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Galectin Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether GALT is over valued or under valued. Whether Galectin Therapeutics Inc is cheap or expensive depends on the assumptions which impact Galectin Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GALT.

What is 5 year return on Galectin Therapeutics Inc's stock?

In the past 10 years, Galectin Therapeutics Inc has provided -0.107 (multiply by 100 for percentage) rate of return.